ALK and non-small cell lung carcinoma: Suppression of mediator complex subunit 12 (MED12), a subunit of the transcriptional MEDIATOR complex in conjunction with cell surface expression of transforming growth factor beta receptor II (TGF-βRII) has been reported to be associated with mechanisms of resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, and chemotherapy to non-small-cell lung cancer (NSCLC) [12].